Epithalon: The Complete Science on Telomere Extension, Anti-Aging, and Longevity

Most longevity supplements gesture vaguely at "cellular aging." Epithalon does something more specific: it is the only synthetic peptide with direct telomerase activation data in human somatic cells. That's a narrow but important distinction — and it's why Epithalon has maintained serious research attention for four decades while other "anti-aging" compounds have come and gone.

The story starts at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s, where Vladimir Khavinson's lab was working on a class of molecules called peptide bioregulators — short peptides extracted from animal tissues to study organ-specific gene regulation. Epithalon was synthesized after Khavinson isolated the active tetrapeptide from bovine pineal gland extract (Epithalamin). The goal was to understand how the aging pineal gland affects the broader aging process. What emerged — telomerase activation, lifespan extension across multiple animal models, melatonin rhythm restoration, and antioxidant upregulation — made Epithalon one of the most studied peptides in the Russian biogerontology literature.

Four primary mechanisms account for Epithalon's effects: telomerase activation, pineal/melatonin axis regulation, antioxidant defense upregulation, and epigenetic gene reprogramming. These are genuinely distinct pathways, not re-descriptions of the same phenomenon.

Honest framing upfront: the overwhelming majority of Epithalon data is Russian-origin, conducted largely by Khavinson's group. Much of it is animal-based. Human trials exist but are small, short-term, and lack independent replication by Western research groups. This is not a compound with FDA-approved indications or Phase III Western RCT data. It is, however, a compound with a deeper evidence base than almost anything else in the research peptide longevity space — if you're willing to engage with the Russian literature and understand its limitations.

What Is Epithalon?

Epithalon (also written Epitalon or Epitalone) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly — alanine, glutamic acid, aspartic acid, and glycine. Molecular weight is approximately 390 Daltons, making it one of the smallest bioactive peptides in active research.

The origin is bovine pineal gland. Khavinson's group isolated a polypeptide complex from bovine pineal extract called Epithalamin — a larger, less defined fraction — and subsequently identified the tetrapeptide sequence responsible for its biological activity. That sequence, when synthesized as Epithalon, was cleaner, more reproducible, and more suitable for systematic research than the whole extract.

Khavinson's research trajectory moved from cell culture and animal models through to human trials over roughly three decades. Animal lifespan studies in rats, mice, and fruit flies came first. Human trials followed, focused on retinal function, lymphocyte biology, and circadian rhythm restoration in elderly cohorts. The research program is extensive by biogerontology standards — but the lack of large-scale Western RCT replication is a real limitation.

Pharmacokinetics. Like most small peptides, Epithalon has negligible oral bioavailability — peptidases in the gastrointestinal tract degrade it before systemic absorption. The standard research routes are subcutaneous (SubQ) injection and intravenous (IV). Plasma half-life is short, measured in minutes to a few hours. This matters because Epithalon's mechanism is not dependent on sustained plasma concentration — it acts on gene promoters and signal transduction pathways that persist long after the peptide has cleared. Downstream effects on gene expression and enzyme activity outlast the plasma curve considerably.

Pineal gland connection. The pineal gland is the source tissue, and this is not coincidental. Epithalon acts as a pineal bioregulator — its effects on the gland's enzyme systems, particularly 5-HT N-acetyltransferase (the rate-limiting enzyme in melatonin synthesis), connect directly to one of its primary mechanisms of action.

Mechanisms

1. Telomerase Activation

Telomeres are the protective caps at the ends of chromosomes — repetitive DNA sequences (TTAGGG in humans) that shorten by 50–200 base pairs with each cell division. When telomere length falls below a critical threshold, the cell enters replicative senescence (the Hayflick limit) or initiates apoptosis. Shorter mean telomere length in circulating blood cells is associated with biological aging, increased all-cause mortality, and accelerated cellular dysfunction. Telomere shortening is, in this sense, a biological clock — measurable, predictable, and linked to healthspan outcomes.

Telomerase is the enzyme that rebuilds telomeres. It is constitutively active in germ cells and stem cells but largely silenced in most somatic (non-reproductive) cells. This silencing is why telomeres shorten progressively with age in peripheral tissues. Reactivating telomerase in somatic cells is one of the most actively pursued strategies in longevity research.

Epithalon's telomerase mechanism centers on TERT — the catalytic subunit of telomerase, which is rate-limiting for telomerase activity. In a landmark 2003 paper, Khavinson's group demonstrated that Epithalon induced TERT expression in human somatic cells (fetal fibroblasts and embryonic kidney cells), with measurable elongation of mean telomere length in treated cells compared to controls. This was followed by in vivo data showing elongated mean telomere length in lymphocytes from elderly subjects following Epithalon treatment — one of the few direct human telomere extension data points in the research peptide literature.

How does this compare to other telomerase activators? TA-65 (cycloastragenol) is the other commonly discussed compound. TA-65 is a small molecule derived from astragalus root that activates telomerase via HSP90 chaperone interaction — it works by rescuing the TERT protein from proteasomal degradation rather than directly upregulating TERT transcription. Epithalon appears to work at the gene promoter level via chromatin-mediated decompaction, allowing transcriptional access to TERT and other longevity-associated genes. These are different entry points in the same pathway, meaning the two compounds are mechanistically non-redundant and potentially additive rather than duplicative.

2. Pineal / Melatonin Axis

The pineal gland is responsible for the nightly melatonin surge that synchronizes the circadian clock. Melatonin production requires the enzyme 5-HT N-acetyltransferase (AA-NAT) to convert serotonin to N-acetylserotonin, which is then methylated to melatonin by hydroxyindole-O-methyltransferase (HIOMT). AA-NAT is the rate-limiting step, and its activity declines significantly with age — particularly after pineal calcification begins, a process that can start in the second decade of life and progresses through aging.

Epithalon stimulates AA-NAT activity, restoring the amplitude and timing of the nightly melatonin rhythm. This matters beyond sleep: melatonin is a direct antioxidant, an immune modulator, and a powerful synchronizer of downstream circadian gene expression in peripheral tissues. When the melatonin rhythm flattens with age, it isn't just sleep quality that degrades — the entire temporal organization of cellular repair, immune function, and metabolic cycling degrades with it.

The cortisol/melatonin balance frames the clinical picture clearly. In a healthy young adult, cortisol peaks in the early morning and declines through the day; melatonin rises in the evening and peaks overnight. With aging and chronic stress, this pattern erodes: cortisol flattens into a blunted but sustained daytime-into-evening elevation, and melatonin amplitude decreases. Epithalon's restoration of melatonin rhythm helps reinstate this reciprocal balance, with downstream effects on sleep architecture, stress response, and immune function.

3. Antioxidant Defense

Reactive oxygen species (ROS) accumulate with aging, and the enzymatic antioxidant defense system — superoxide dismutase (SOD), catalase, glutathione peroxidase — declines in parallel. This is not incidental: mitochondrial ROS production increases as mitochondrial membrane integrity degrades, and the reduced enzymatic capacity to neutralize ROS accelerates the feedback loop of oxidative damage.

Epithalon has been shown to upregulate both SOD and catalase activity in multiple tissue models. Khavinson's 1995 data on retinal epithelium is particularly notable: Epithalon treatment significantly reduced lipid peroxidation markers and restored enzymatic antioxidant capacity in aged retinal cells — a tissue where oxidative damage accumulates to produce age-related macular degeneration and retinal pathology. This antioxidant pathway is mechanistically similar to what GHK-Cu achieves through SOD1 and catalase upregulation, though through a distinct upstream mechanism.

The mitochondrial dimension is important here. Mitochondrial membrane permeability increases with age, allowing electron leak and excess superoxide generation. By upregulating SOD (which converts superoxide to hydrogen peroxide) and catalase (which converts hydrogen peroxide to water), Epithalon reduces the net mitochondrial ROS load — slowing one of the central feedback loops of cellular aging at the source.

4. Gene Expression and Epigenetic Reprogramming

Perhaps the most architecturally interesting aspect of Epithalon is its apparent action at the chromatin level. Peptide bioregulators in general — and Epithalon specifically — appear to interact with histones and chromatin architecture, promoting decompaction of gene promoter regions that become hypermethylated or compacted with aging. This decompaction restores transcriptional access to genes whose silencing is associated with cellular senescence.

The practical consequence: Epithalon doesn't just activate telomerase in isolation. A 2012 Khavinson gene array analysis identified a broader pattern of gene expression changes in treated cells — including restoration of IGF-1 signaling pathway sensitivity, modulation of the p53/Bcl-2 balance toward anti-apoptosis (increased Bcl-2, reduced excessive p53 activation), and upregulation of multiple DNA repair genes. IGF-1 sensitivity restoration is relevant to tissue maintenance and anabolic signaling in aging individuals, where receptor downregulation (rather than ligand deficiency) is often the actual limiting factor.

The p53/Bcl-2 balance requires some nuance. p53 is a tumor suppressor, and reducing its activation sounds counterintuitive — but in aging somatic cells, excessive p53-driven apoptosis can eliminate cells that could otherwise be repaired, depleting stem cell pools and accelerating tissue aging. Epithalon's shift toward Bcl-2-mediated survival in stressed cells represents a physiological recalibration, not oncogenic bypass — and it is distinct from the constitutive TERT promoter mutations that drive cancer telomerase overactivation.

If you're building a longevity stack, the Peptide Stacking Guide walks through cycling Epithalon with GH peptides and repair compounds — including the Khavinson dual-bioregulator protocol with Thymalin, timing windows, and how to layer Epithalon into a comprehensive longevity protocol. $14.99.

Longevity and Anti-Aging Benefits

Telomere Biology and the Cancer Question

Before diving into the lifespan data, the most common concern deserves a direct answer: does telomerase activation increase cancer risk?

The short answer is no, and the reasoning matters. When telomeres shorten below the critical threshold, cells enter senescence or apoptosis — this is actually a tumor suppressor mechanism. Senescent cells cannot proliferate indefinitely, which prevents runaway cell division. Longer telomeres in somatic cells do not directly create cancer risk; they restore the replicative capacity that aging has depleted, allowing cells to function normally rather than senescing prematurely.

Most cancers do upregulate telomerase, but via oncogenic mutations in the TERT promoter (most commonly TERT C228T and C250T, found in glioblastoma, melanoma, and bladder cancer) — constitutive re-expression that bypasses normal gene regulation entirely. The TERT upregulation Epithalon produces is epigenetically mediated and reversible, not mutation-driven. The experimental record aligns: no increase in tumor incidence in Epithalon-treated animals across multiple long-term studies, and in fact the opposite direction of effect.

Animal Lifespan Data

The most striking lifespan data comes from Anisimov et al. (2003), who conducted a long-term study in spontaneously hypertensive (SHR) female rats treated with Epithalon. The treated group showed approximately 30% longer mean and maximum lifespan compared to controls — a result that would be extraordinary if replicated in humans. In Drosophila (fruit fly) models, mean lifespan extension in the 15–20% range has been reported. In rat studies, both mean lifespan extension and slowing of age-related histological changes in multiple tissues were documented.

These results deserve appropriate context: SHR rats are a specific cardiovascular disease model rather than a standard aging model, and extrapolating lifespan data from flies and rats to human longevity is a long bridge. But the consistency of direction across species — and the magnitude — makes this data meaningful even with those caveats.

Human Data

Human data is limited but real. Khavinson's 2010 study in elderly cohorts (65+) demonstrated improvements in retinal function — visual acuity and electroretinogram amplitude — following Epithalon treatment. This is some of the most useful human data for any longevity peptide because it uses a direct functional measure in a high-oxidative-stress tissue with strong mechanistic rationale (the 1995 retinal antioxidant data predicts exactly this outcome).

The 2012 lymphocyte telomere study documented measurable increases in mean telomere length in peripheral blood lymphocytes of elderly subjects following Epithalon treatment — a direct molecular endpoint. This is the human data most commonly cited in biohacker literature, and it is real. The caveats are also real: small sample size, no independent replication, and telomere length in blood cells is a biomarker, not a confirmed longevity endpoint.

Honest caveat: There are no large-scale, independently replicated RCTs with human longevity as a primary endpoint. The available human data supports biological plausibility and shows biomarker movement in the right direction, but direct clinical translation to longevity outcomes in Western populations has not been established.

Immune Reconstitution

Epithalon has shown T-cell proliferation effects and increased NK (natural killer) cell cytotoxicity in both animal and human models. NK cells are the frontline of anti-cancer immune surveillance — they identify and eliminate cells expressing aberrant surface markers, including early malignant cells, before the adaptive immune system has been primed to them. Age-related NK cell dysfunction is a well-recognized contributor to increased cancer incidence in older adults. Epithalon's immune reconstitution effects provide a plausible mechanistic pathway connecting the peptide's biology to the reduced tumor incidence observed in the animal lifespan data.

Skin and Tissue

Outside of telomeres, Epithalon's strongest human data is in tissue preservation — particularly retinal epithelium (the 1995 antioxidant data and 2010 functional improvement data) and in collagen synthesis upregulation documented in dermal fibroblast models, consistent with Epithalon's chromatin remodeling effects on extracellular matrix genes.

Sleep and Circadian Regulation

The pineal mechanism isn't just about telomeres — it produces one of Epithalon's most practically accessible effects: restoration of melatonin rhythm in aging individuals.

When the pineal gland calcifies and AA-NAT activity declines, the melatonin surge that normally drives sleep onset and maintains sleep architecture flattens. This shows up clinically as reduced sleep depth (less slow-wave sleep), earlier morning awakening, difficulty maintaining sleep continuity, and — critically for the athlete or biohacker — reduced nocturnal GH pulse amplitude, which is SWS-dependent. The downstream consequence is impaired cellular repair, reduced immune function during sleep, and faster biological aging.

Epithalon restores AA-NAT activity and with it the melatonin surge amplitude — not by exogenously supplying melatonin, but by restoring the gland's capacity to produce it endogenously. This distinction matters: exogenous melatonin shifts sleep timing and reduces latency but doesn't restore the gland's synthetic capacity or the full amplitude of the rhythm. Epithalon addresses the upstream enzyme dysfunction rather than compensating downstream.

DSIP synergy. DSIP (delta sleep-inducing peptide) works through a completely different mechanism — it modulates the hypothalamic-pituitary axis to amplify slow-wave sleep architecture and normalize cortisol rhythms, without any GABA-A sedation. Epithalon restores the melatonin rhythm via the pineal gland. These are complementary mechanisms operating at different nodes in the sleep-circadian system. Used together, they address both the circadian amplitude deficiency (Epithalon/melatonin axis) and the sleep architecture quality problem (DSIP/SWS amplification) — without mechanistic overlap. The standard stack uses DSIP at 100–200 mcg alongside the Epithalon 10-day cycle.

Practical applications: jet lag correction (melatonin rhythm reset after time-zone transition), shift-work circadian disruption, age-related sleep fragmentation, and as a circadian base layer for recovery-focused longevity protocols. The circadian benefits typically become apparent within the first 3–5 days of a 10-day cycle. For a complete breakdown of the DSIP mechanism, circadian timing protocols, and stack structures, see the DSIP article.

Cancer and Immune Surveillance

The Anisimov 2003 dataset is the most cited source for Epithalon's cancer-related findings. Beyond the lifespan data, Anisimov documented reduced spontaneous tumor frequency in treated mice compared to controls. The connecting mechanism is primarily NK cell-mediated: Epithalon's enhancement of NK cell cytotoxicity improves the immune system's capacity to identify and eliminate pre-malignant and early-stage malignant cells before they establish. This is immune surveillance — the prophylactic prevention of tumor development — not tumor treatment.

NK cells operate independently of antigen presentation, meaning they can act against cancer cells before the adaptive immune system has developed an antigen-specific response. This makes NK activity the earliest line of anti-cancer defense. Age-related decline in NK function is a major contributor to the rising cancer incidence seen in older adults. Epithalon's NK reconstitution effect connects directly to this biology.

How does this compare to Thymosin Alpha-1? Thymosin Alpha-1 works primarily through the TLR9/dendritic cell/adaptive arm — activating antigen presentation, Th1 polarization, and T-cell cytotoxicity against established tumor antigens. These are different mechanisms in different immune compartments: Epithalon is primarily an innate surveillance restorative; Thymosin Alpha-1 is an adaptive arm activator. Complementary, not redundant. The Immune Health Hub covers the full immune peptide landscape and how these compounds interact.

Honest framing: Epithalon is not a cancer treatment. The animal tumor data is in spontaneous models, not implanted tumor models, and the mechanism is prophylactic immune surveillance, not therapeutic oncology. Anyone with active cancer should discuss any peptide protocol with their oncologist before proceeding.

Epithalon vs. Other Longevity Peptides

Dosing Protocols

Epithalon is dosed in milligrams — it requires more material per dose than many research peptides, which are typically micrograms.

Protocol 1: Standard Longevity Cycle

Dose: 10 mg/day SubQ Duration: 10 consecutive days Frequency: 1–2 cycles per year Timing: No strong timing requirement; morning or evening both used in the Khavinson protocol

This is the foundational protocol derived directly from Khavinson's research design. The 10-day burst is not arbitrary — it matches the kinetics of the gene expression changes induced, with downstream effects on telomerase activity and antioxidant enzymes persisting well beyond the dosing window. Running continuous daily Epithalon has no established precedent in the literature and is not recommended. One cycle per year for long-term maintenance; two cycles per year if actively targeting telomere maintenance or circadian restoration as primary goals.

Protocol 2: Sleep + Circadian Reset

Dose: 5–10 mg/day SubQ Duration: 10 days Timing: 30 minutes before sleep Stack: DSIP 200 mcg SubQ at the same time

For sleep architecture restoration, circadian rhythm reset (jet lag, shift work, age-related sleep fragmentation), or as a recovery-focused protocol. Epithalon's melatonin-restoration mechanism pairs directly with DSIP's SWS amplification — the two peptides operate on different nodes in the sleep-circadian system, making the combination non-redundant and additive. Run this as one 10-day block; repeat as needed based on sleep quality and circadian entrainment.

Protocol 3: Longevity Stack (Khavinson Dual-Bioregulator)

Structure: Epithalon 10 mg/day × 10 days → 4-week break → Thymalin 10 mg/day × 10 days → 4-week break → repeat Frequency: 2 complete alternating cycles per year Rationale: This is the Khavinson "dual bioregulator" longevity protocol — alternating the pineal bioregulator (Epithalon) and the thymic bioregulator (Thymalin). The two organs represent distinct axes of the aging process: the pineal drives circadian regulation, telomere biology, and antioxidant defense; the thymus drives immune aging and T-cell reconstitution. Khavinson's research found greater longevity effects with alternating pineal + thymic peptide treatment than with either compound alone — the organs are functionally connected, and addressing both simultaneously (via alternating cycles) appears to produce synergy.

Reconstitution: Standard bacteriostatic water (BAC water). For a 10 mg vial, add 1–2 mL BAC water for a 5–10 mg/mL concentration. See the reconstitution guide for full protocol including syringe selection, injection site technique, and storage notes.

Storage: Lyophilized (freeze-dried) powder is stable at -20°C for 12–24 months. Reconstituted solution should be refrigerated at 4°C and used within 30 days.

Safety

Across the body of Khavinson research, Epithalon has demonstrated a favorable tolerability profile. No serious adverse events were reported in published trials. The most commonly noted side effect is injection site reactions — redness, mild swelling — that are self-limiting and common to any SubQ injection protocol.

Telomerase and cancer — the direct answer. The theoretical concern that activating telomerase could promote cancer is biologically understandable, but it is not supported by the experimental data. The TERT upregulation from Epithalon appears to occur via physiological epigenetic decompaction — a reversible, transcription-level effect — which is distinct from the constitutive TERT promoter mutations driving telomerase overactivation in cancer cells. Crucially, no increase in tumor incidence was observed in Epithalon-treated animals across multiple long-term studies; reduced tumor incidence was the actual finding.

What we don't know: There is no long-term human follow-up data extending beyond the timeframes of Khavinson's trials. Ten-plus year human outcome data simply does not exist for this compound. The absence of evidence is not evidence of absence — but it is a real limitation.

Contraindications: Pregnancy (safety not established); active cancer (consult oncologist before any peptide protocol); pediatric use (no data, not appropriate).

Frequently Asked Questions

Is Epithalon the same as Epitalon?

Yes. "Epithalon" and "Epitalon" are different English transliterations of the Russian word Эпиталон. You'll also occasionally see "Epitalone" in European literature. The peptide is identical regardless of spelling: Ala-Glu-Asp-Gly, the synthetic tetrapeptide originally developed by Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. All three transliterations refer to the same compound and appear interchangeably across the research literature.

Can Epithalon cause cancer by activating telomerase?

This is the right question to ask, and the answer is no — for reasons rooted in the biology rather than reassurance. Cancer-driving telomerase activation typically involves somatic mutations in the TERT promoter (most commonly TERT C228T and C250T, found in glioblastoma, melanoma, and bladder cancer) that constitutively re-express TERT regardless of normal regulatory signals. Epithalon's mechanism is different: it works at the chromatin level via epigenetic decompaction that restores access to gene promoters in aging cells — physiological TERT restoration, not oncogenic TERT mutation. The experimental evidence aligns: no tumor incidence increase across long-term animal studies, with reduced tumor frequency actually observed in the Anisimov 2003 dataset.

How does Epithalon compare to TA-65 / cycloastragenol?

Both activate telomerase, but through different mechanisms and from different evidence bases. TA-65 is a small molecule derived from astragalus root (cycloastragenol is the active component) that activates telomerase by binding HSP90 and reducing TERT protein degradation — it stabilizes existing TERT protein rather than upregulating TERT transcription. Epithalon works at the gene promoter level via chromatin decompaction, affecting TERT transcription directly. These are mechanistically non-redundant: TA-65 is post-translational (protein stability), Epithalon is epigenetic/transcriptional (gene expression). Stacking them is biologically rational since they target complementary nodes, though combined human data does not exist. From an evidence standpoint, Epithalon has direct human somatic cell and human subject data from Khavinson; TA-65 has independent replication from Western groups including Maria Blasco's lab at the CNIO.

Does Epithalon need to be cycled?

Yes. The evidence base for Epithalon is built entirely on 10-day burst cycles, not continuous daily administration. The 10-day protocol appears to match the kinetics of the downstream gene expression changes, allowing appropriate signaling dynamics without pathway overstimulation. Continuous daily use has no established precedent and is not consistent with the Khavinson protocol design. The standard maintenance frequency is 1–2 cycles per year, with downstream effects persisting well beyond the dosing window.

Can I stack Epithalon with Thymalin?

Yes — this combination is the Khavinson "dual bioregulator" longevity protocol and represents the most evidence-backed multi-peptide longevity approach in the Russian literature. Thymalin (thymic bioregulator) and Epithalon (pineal bioregulator) are run in alternating cycles rather than simultaneously, targeting the two organ systems most central to the aging process from Khavinson's framework: the thymus (immune aging, T-cell reconstitution) and the pineal gland (circadian biology, telomere maintenance). The two compounds complement each other at different axes of the aging process, and Khavinson's research found greater longevity effects from the combination than from either compound alone.

Conclusion

Epithalon occupies a unique position in the longevity peptide space because its mechanisms are specific rather than vague. Telomerase activation via TERT upregulation, pineal gland melatonin rhythm restoration, antioxidant enzyme upregulation, and epigenetic gene expression reprogramming are four distinct and well-characterized pathways — not marketing descriptions of "cellular rejuvenation."

The evidence base is real: Khavinson's decades of research include direct human data on lymphocyte telomere length, retinal function, and circadian restoration, alongside robust animal lifespan data showing 30% extension in SHR rat models. The limitations are equally real: the data is overwhelmingly Russian-origin, independent Western RCT replication is absent, and no human longevity endpoint has been established in a large trial. These caveats don't invalidate the biology — they define where confidence is warranted and where humility is required.

For biohackers building a serious longevity protocol, Epithalon belongs on the shortlist — particularly for the pineal/circadian layer, telomere maintenance, and as the anchor of the Khavinson dual-bioregulator pairing with Thymalin. The Pinealon article covers the adjacent compound for brain protection and cognitive longevity through the same pineal axis. The Beginner's Guide is the right starting point if you're earlier in the research process.

The Peptide 101: Complete Bundle — $19.99. The Complete Bundle gives you both the Beginner's Guide and the Stacking Guide — everything you need to build your first evidence-based longevity protocol, including the Epithalon + Thymalin dual-bioregulator cycle, GH peptide layering, and the full longevity stack framework.

This content is for educational purposes only and does not constitute medical advice. Epithalon is a research peptide and is not FDA-approved for any human therapeutic indication. The dosing protocols described are derived from preclinical research and the Khavinson research group's published work — not from approved clinical guidelines. Consult a qualified healthcare provider before beginning any peptide protocol, particularly if you have a personal or family history of cancer, are pregnant, or are taking immunomodulatory medications.